Copyright © 2021. Inderes Oyj. All rights reserved.

Redeye has a positive view of Cantargia's obtaining orphan drug status. It provides some benefits, the most important of which are described in our comment.

Lähde: Finwire News

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.